RIGL Financial Facts
Income (loss) from operations: -25.71MInterest income: 136K
See Full Income Statement
Total liabilities and stockholders' equity: 282.94M
Prepaid expenses and other current assets: 2.96M
See Full Balance Sheet
Earnings History for Rigel Pharmaceuticals, Inc. (RIGL)
|
Expand Research on RIGL
| Next EPS Date | 8/6/13 *Est. | EPS Growth Rate | +9.4% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +0.7% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.2% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/5/13 | Q412 | -$0.30 | N/A | N/A | N/A | N/A | N/A / N/A | N/A | -32.6% | Details | |
5/1/12  |
Q112 | -$0.32 | -$0.31 | -$0.01 | $750K | $620K | N/A / N/A | N/A | -40.5% | Details | |
| 5/7/13 | Q113 | -$0.29 | -$0.30 | +$0.01 | N/A | $1.73M | N/A / N/A | N/A | -2.1% | Details | |
| 11/6/12 |
Q312 | -$0.36 | -$0.37 | +$0.01 | N/A | $750K | N/A / N/A | N/A | -46.6% | Details | |
| 11/1/11 |
Q311 | -$0.25 | N/A | N/A | $4.35M | $72.28K | N/A / N/A | N/A | -41.4% | Details | |
| 3/5/12 | Q411 | -$0.36 | -$0.28 | -$0.08 | N/A | $2.23M | N/A / N/A | N/A | -52.6% | Details | |
| 5/3/11 | Q111 | -$0.40 | -$0.36 | -$0.04 | N/A | $630K | N/A / N/A | N/A | -49.5% | Details | |
| 8/7/12 |
Q212 | -$0.35 | -$0.35 | $0.00 | $1.15M | $550K | N/A / N/A | N/A | -57.3% | Details |
